Mr. Messerlian is the Chief Executive Officer and member of the Board of Directors

Serge Messerlian brings over 25 years of experience in serving patients and building cutting edge medicines and technologies in the life science industry across a range of roles and therapeutic areas, including oncology, hematology, immunology and rare disease. Before joining Plexium, Serge was CEO of Creyon Bio, and CEO of Teon Therapeutics. Prior to that, as President of Oncology at Johnson & Johnson, he set the strategic direction for the organization, its key brands, and pipeline programs across hematology and solid tumors, as well as platforms including cell therapies. He also held executive leadership roles at Johnson & Johnson’s Actelion, Baxalta, and Baxter International. Serge is an Operating Partner at DCVC Bio.

Serge holds a B.Sc. degree in physiology & biotechnology and a M.Sc. degree in molecular genetics, both from McGill University, and an MBA from the University of Toronto.